Weekly Investment Analysts’ Ratings Updates for GE HealthCare Technologies (GEHC)

Several brokerages have updated their recommendations and price targets on shares of GE HealthCare Technologies (NASDAQ: GEHC) in the last few weeks:

• 5/1/2026 – GE HealthCare Technologies had its price target lowered by BNP Paribas Exane from $95.00 to $88.00.
• 4/30/2026 – GE HealthCare Technologies was given a new $80.00 price target by Evercore Inc.
• 4/30/2026 – GE HealthCare Technologies had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $85.00 price target on the stock.
• 4/30/2026 – GE HealthCare Technologies had its price target lowered by Barclays PLC from $87.00 to $78.00. They now have an “equal weight” rating on the stock.
• 4/30/2026 – GE HealthCare Technologies was downgraded by The Goldman Sachs Group, Inc. from “buy” to “neutral”. They now have a $65.00 price target on the stock, down from $81.00.
• 4/30/2026 – GE HealthCare Technologies had its price target lowered by Piper Sandler from $88.00 to $74.00.
• 4/30/2026 – GE HealthCare Technologies had its price target lowered by Mizuho from $90.00 to $80.00.
• 4/30/2026 – GE HealthCare Technologies had its price target lowered by HSBC Holdings plc from $100.00 to $90.00.
• 4/30/2026 – GE HealthCare Technologies had its price target lowered by Jefferies Financial Group Inc. from $105.00 to $90.00.
• 4/30/2026 – GE HealthCare Technologies had its price target lowered by Rothschild & Co Redburn from $110.00 to $98.00.
• 4/30/2026 – GE HealthCare Technologies had its price target lowered by JPMorgan Chase & Co. from $80.00 to $65.00. They now have a “neutral” rating on the stock.
• 4/30/2026 – GE HealthCare Technologies had its price target lowered by Citigroup Inc. from $80.00 to $65.00. They now have a “neutral” rating on the stock.
• 4/30/2026 – GE HealthCare Technologies had its price target lowered by Wells Fargo & Company from $97.00 to $75.00. They now have an “overweight” rating on the stock.
• 4/29/2026 – GE HealthCare Technologies was given a new $80.00 price target by Stifel Nicolaus.
• 4/29/2026 – GE HealthCare Technologies had its price target lowered by BTIG Research from $85.00 to $80.00. They now have a “buy” rating on the stock.
• 4/21/2026 – GE HealthCare Technologies had its “buy” rating reaffirmed by BTIG Research. They now have a $85.00 price target on the stock.
• 4/17/2026 – GE HealthCare Technologies had its price target lowered by Piper Sandler from $96.00 to $88.00. They now have an “overweight” rating on the stock.
• 4/13/2026 – GE HealthCare Technologies had its price target lowered by Mizuho from $95.00 to $90.00. They now have an “outperform” rating on the stock.
• 4/9/2026 – GE HealthCare Technologies had its price target lowered by The Goldman Sachs Group, Inc. from $97.00 to $81.00. They now have a “buy” rating on the stock.
• 4/6/2026 – GE HealthCare Technologies had its price target lowered by Evercore Inc from $98.00 to $85.00. They now have an “outperform” rating on the stock.
• 3/21/2026 – GE HealthCare Technologies was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/19/2026 – GE HealthCare Technologies had its “buy” rating reaffirmed by BTIG Research. They now have a $91.00 price target on the stock.

GE HealthCare Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Friday, April 3rd will be issued a $0.035 dividend. This represents a $0.14 annualized dividend and a dividend yield of 0.2%. The ex-dividend date is Thursday, April 2nd. GE HealthCare Technologies’s dividend payout ratio (DPR) is presently 3.35%.

Insider Activity

In other news, insider Frank R. Jimenez purchased 1,750 shares of the business’s stock in a transaction dated Thursday, April 30th. The shares were acquired at an average price of $60.45 per share, for a total transaction of $105,787.50. Following the completion of the acquisition, the insider directly owned 93,932 shares of the company’s stock, valued at $5,678,189.40. The trade was a 1.90% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Watkin Phoebe L. Yang purchased 1,000 shares of GE HealthCare Technologies stock in a transaction that occurred on Friday, May 8th. The stock was purchased at an average price of $63.01 per share, with a total value of $63,010.00. Following the transaction, the director owned 13,702 shares in the company, valued at $863,363.02. This represents a 7.87% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders acquired 10,229 shares of company stock valued at $619,190. 0.36% of the stock is currently owned by insiders.

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.